Isotechnika Pharma (AUPH) Stock Rating Lowered by BidaskClub

Isotechnika Pharma (NASDAQ:AUPH) (TSE:AUP) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.

A number of other analysts also recently issued reports on AUPH. Cantor Fitzgerald set a $16.00 price objective on shares of Isotechnika Pharma and gave the company a “buy” rating in a report on Wednesday, May 16th. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Isotechnika Pharma in a report on Wednesday, May 2nd. Zacks Investment Research downgraded shares of Isotechnika Pharma from a “hold” rating to a “sell” rating in a report on Wednesday, April 11th. Royal Bank of Canada assumed coverage on shares of Isotechnika Pharma in a report on Thursday, February 8th. They issued an “outperform” rating and a $9.00 price objective for the company. Finally, ValuEngine raised shares of Isotechnika Pharma from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Isotechnika Pharma presently has an average rating of “Buy” and an average target price of $10.92.

Isotechnika Pharma opened at $5.83 on Wednesday, according to Marketbeat Ratings. The stock has a market capitalization of $509.35 million, a price-to-earnings ratio of -6.34 and a beta of 2.26. Isotechnika Pharma has a 12-month low of $4.41 and a 12-month high of $7.68.

Isotechnika Pharma (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.05 million. Isotechnika Pharma had a negative net margin of 8,193.08% and a negative return on equity of 20.67%. equities research analysts expect that Isotechnika Pharma will post -0.7 earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of the company. Cutler Capital Management LLC lifted its holdings in shares of Isotechnika Pharma by 25.0% during the 4th quarter. Cutler Capital Management LLC now owns 50,000 shares of the biotechnology company’s stock worth $226,000 after acquiring an additional 10,000 shares during the period. Stifel Financial Corp lifted its holdings in shares of Isotechnika Pharma by 98.4% during the 1st quarter. Stifel Financial Corp now owns 21,718 shares of the biotechnology company’s stock worth $113,000 after acquiring an additional 10,772 shares during the period. Kazazian Asset Management LLC lifted its holdings in shares of Isotechnika Pharma by 11.6% during the 4th quarter. Kazazian Asset Management LLC now owns 156,126 shares of the biotechnology company’s stock worth $707,000 after acquiring an additional 16,189 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of Isotechnika Pharma by 13,197.5% during the 3rd quarter. Wells Fargo & Company MN now owns 26,595 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 26,395 shares during the period. Finally, DRW Securities LLC bought a new stake in shares of Isotechnika Pharma during the 1st quarter worth approximately $162,000. 25.58% of the stock is owned by institutional investors.

About Isotechnika Pharma

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has partnership agreements with Paladin Labs Inc and 3SBio, Inc The company was formerly known as Isotechnika Pharma Inc and changed its name to Aurinia Pharmaceuticals Inc in October 2013.

Analyst Recommendations for Isotechnika Pharma (NASDAQ:AUPH)

Receive News & Ratings for Isotechnika Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isotechnika Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply